To recover your password please fill in your email address
Please fill in below form to create an account with us
A randomised phase II study of carboplatin and bevacizumab in recurrent glioblastoma multiforme.
|
Trial Summary: |
The Cabaret study aimed to measure the effectiveness of the different treatment regimens in terms of survival and wellbeing for patients with recurrent glioblastoma multiforme (a type of brain tumour). |
|
Supported By: |
Roche Products Pty Limited; NHMRC CTC; COGNO |
|
Eligibility: |
Patients with recurrent grade IV glioma (glioblastoma multiforme) who have had radiotherapy and temozolomide chemotherapy. |
|
Registration ID: |
ACTRN12610000915055 |
|
Participation: |
Australia |
|
Australian Lead Group: |
COGNO |
|
Status: |
Closed |
|
Activation Date: |
05/11/2010 |
|
Chairs: |
Dr Kathryn Field (AU) |
|
Contact: |